Drugs / BGB-26808
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05981703 | Sep 2023 → Sep 2027 expected | neoplastic disease or syndrome | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-26808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05981703 ↗ |
| Action | Inhibit | “HPK1 inhibitor BGB-26808” NCT05981703 ↗ |
| Route | Oral | “Planned doses administered orally as a tablet daily.” NCT05981703 ↗ |